Special Article
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases
Patrick Garnero,
Jean-Charles Rousseau,
Pierre D. Delmas,
Corresponding Author
Patrick Garnero
INSERM Unit 403, and Synarc, Lyon, France
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 Lyon Cedex 03, FranceSearch for more papers by this authorJean-Charles Rousseau
INSERM Unit 403, and Synarc, Lyon, France
Search for more papers by this authorPatrick Garnero,
Jean-Charles Rousseau,
Pierre D. Delmas,
Corresponding Author
Patrick Garnero
INSERM Unit 403, and Synarc, Lyon, France
INSERM Unit 403, Hôpital E. Herriot, Pavillon F, 69437 Lyon Cedex 03, FranceSearch for more papers by this authorJean-Charles Rousseau
INSERM Unit 403, and Synarc, Lyon, France
Search for more papers by this authorFirst published: 02 April 2001
Citations: 221
43:5<953::aid-anr1>3.0.co;2-q.fp.png)
REFERENCES
- 1 Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997; 40: 723–7.
- 2 Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5 years of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996; 35: 1106–15.
- 3 Robey PG, Boskey AL. The biochemistry of bone. In: R Marcus, D Feldman, J Kelsey, editors. Osteoporosis. San Diego: Academic Press; 1996. p. 95–183.
- 4 Garnero P, Delmas PD. Biochemical markers of bone turnover: applications for osteoporosis. In: N Watts, editors. Endocrinology and metabolism clinics of North America: osteoporosis. Philadelphia: WB Saunders; 1998. p. 303–23.
- 5 Okada Y, Naka K, Minamoto T, Ueda Y, Oda Y, Nakanishi I, et al. Localization of type VI collagen in the lining cell layer of normal and rheumatoid synovium. Lab Invest 1990; 63: 647–56.
- 6 Levick JR, Price FM, Mason RM. Synovial matrix—synovial systems of joints. In: WD Comper, editor. Extracellular matrix. Vol. 1. Tissue function. Amsterdam: OPA; 1996. p. 328–77.
- 7 Levick JR. Synovial fluid dynamics: the regulation of volume and pressure. In: A Maroudas, EJ Holborow, editors. Studies in joint disease 2. London: Pitman Medical; 1983. p. 153–240.
- 8
Ribitsh VO.
Viscostatic behavior of synovial fluids and artificial replacements. In:
VC Mow,
SLY Woo,
A Ratcliffe, editors.
Biomechanics of diarthrodial joints.
Vol. II. New York:
Springer-Verlag;
1990.
287–304.
10.1007/978-1-4612-3450-0_12 Google Scholar
- 9 Worral JG, Bayliss MT, Edwards JCW. Zonal distribution of sulfated proteoglycans in normal and rheumatoid synovium [abstract]. Br J Rheumatol 1990; Suppl 2: 34.
- 10 Heinegard D, Goldberg A. Structure and biology of cartilage and bone noncollagenous macromolecules. FASEB J 1989; 3: 2042–51.
- 11 Mendler M, Eich-Bender S, Vaughan L, Winterhalter KH, Bruckner P. Cartilage contains mixed fibrils of collagen type II, IX and XI. J Cell Biol 1989; 108: 191–7.
- 12 Fassler R, Schnegelsberg PN, Dausman J, Shinya T, Muragaki Y, McCarthy MT, et al. Mice lacking alpha 1 (IX) collagen develop non-inflammatory degenerative joint disease. Proc Natl Acad Sci U S A 1994; 91: 4571–6.
- 13 Robins S. Crosslinking of collagen: isolation, structural characterization and glycosylation of pyridinolines. Biochem J 1983; 215: 167–73.
- 14 Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998; 41: 110–21.
- 15 Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenase in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 1534–45.
- 16 Reboul P, Pelletier J-P, Tardif G, Cloutier J-M, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not synoviocytes. J Clin Invest 1996; 97: 2011–9.
- 17 Mitchell PG, Magna HA, Reeves LM, Lopresi-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761–8.
- 18
Watanabe H,
Yamada Y,
Kimata K.
Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function.
J Biochem
1998;
124:
667–83.
10.1093/oxfordjournals.jbchem.a022166 Google Scholar
- 19 Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992; 89: 1512–6.
- 20 Bourdon MA, Krusius T, Campbell S, Schwartz NB, Ruoslahti E. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc Natl Acad Sci U S A 1987; 84: 3194–8.
- 21 Krueger RC, Fields TA, Hildreth J IV, Schwartz NB. Chick cartilage chondroitin sulfate proteoglycan core protein: generation and characterization of peptides and specificity for glycosaminoglycan attachment. J Biol Chem 1990; 265: 12075–87.
- 22 Doege KJ, Coulter SN, Meek LM, Maslen K, Wood JG. A human specific polymorphism in the coding region of aggrecan gene: variable number of tandem repeats produce a range of core protein sizes in the general population. J Biol Chem 1997; 272: 13974–9.
- 23 Plass AH, Wong-Palms S, Roughley PJ, Midura RJ, Hascall VC. Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan. J Biol Chem 1997; 272: 20603–10.
- 24 Debri E, Reinholt FP, Heinegard D, Mengarelliholm S, Norgard M, Svensson O. Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop 1996; 330: 251–60.
- 25 Saxne T, Zunino L, Heinegård D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995; 38: 82–90.
- 26 Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95: 1071–7.
- 27 Petersson IF, Boegard T, Dahlstrom J, Svensson B, Heinegard D, Saxne T. Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. Osteoarthritis Cartilage 1998; 6: 33–9.
- 28 Petersson IF, Boegard T, Svensson B, Heinegard D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998; 37: 46–50.
- 29 Conrozier T, Saxne T, Shan Sei Fan C, Mathieu P, Tron A-M, Heinegard D, et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 1998; 9: 527–32.
- 30 Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P. Uncoupling of bone metabolism in rheumatoid arthritis with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 1999; 24: 381–5.
- 31 Eyre DR, Koob TJ, van Ness KP. Quantitation of hydroxypyridinium crosslinks in collagen by high performance liquid chromatography. Anal Biochem 1984; 137: 380–8.
- 32 Takahashi M, Kushida K, Hoshino H, Sizuki M, Sano M, Miyamoto S, et al. Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 1996; 55: 324–7.
- 33 Colwell A, Eastell R. Renal clearance of free and conjugated pyridinium crosslinks of collagen. J Bone Miner Res 1996; 11: 1976–80.
- 34 Black D, Marabani M, Sturrock RD, Robins S. Urinary excretion of the hydroxypyridinium cross-links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 641–4.
- 35 Kollerup G, Hansen M, Horslev-Petersen K. Urinary hydroxypyridinium crosslinks of collagen in rheumatoid arthritis: relation to disease activity and effects of methylprednisolone. Br J Rheumatol 1994; 33: 816–20.
- 36 Thompson PW, Spector TD, James IT, Henderson E, Hart DJ. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. BMJ 1992; 31: 759–61.
- 37 Dodge GR, Poole AR. Immunohistochemical detection and analysis of type II degradation in human normal, rheumatoid, and osteoarthritic cartilage and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989; 83: 647–61.
- 38 Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994; 93: 1772–32.
- 39 Saltarelli MJ, Johnson KS, Pickering E, Otterness IG, Vazquez-Abad MD, Woodworth TG. Measurement of urinary type II collagen neoepitope levels in rheumatoid arthritis patients to assess joint status [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S249.
- 40 Woodworth TG, Otterness IG, Johnson K, Pickering E, Saltarelli MJ. Urinary type II collagen neoepitope in osteoarthritis patients is associated with disease severity [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S258.
- 41 Eyre DR, Shao P, Vosberg-Smith K, Weis M, Shaffer K, Yoshihara P. Cross-linked telopeptides from collagen types I, II and III in human urine [abstract]. J Bone Miner Res 1995; S1: S413.
- 42 Moskowitz RW, Holderbaum D, Atley LM, Eyre DR. Type II collagen C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S352.
- 43 Garnero P, Gineyts E, Christgau S, Delmas PD. Urinary type II collagen C-telopeptide breakdown products as a marker of cartilage degradation in rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S128.
- 44 Garnero P, Vergnaud P, Delmas PD. Amino terminal propeptide of type I collagen (PINP) is a more sensitive marker of bone turnover than C-terminal propeptide in osteoporosis [abstract]. J Bone Miner Res 1997; 12 Suppl 1: S497.
- 45 Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 12: 2115–25.
- 46 Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol 1996; 23: 1765–9.
- 47 Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M, Poole R. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999; 42: 129–36.
- 48 Bleasel JF, Poole AR, Heinegård D, Saxne T, Holderbaum D, Ionescu M, et al. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 1999; 42: 39–45.
- 49 Sandell LJ, Morris N, Robbins JR, Goldring MR. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. J Cell Biol 1991; 114: 1307–19.
- 50 Aigner T, Zhu Y, Chansky HH, Matsen FA III, Maloney WJ, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999; 42: 1443–50.
- 51 Saxne T, Heinegard D, Wollheim FA, Petterson H. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet 1985; 2: 127–8.
- 52 Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker turnover detectable in synovial fluid and blood. Br J Rheumatol 1992; 31: 583–91.
- 53 Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentration of cartilage oligomeric matrix protein: a prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31: 593–8.
- 54 Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36: 181–9.
- 55 Saxne T, Heinegård D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum 1992; 35: 385–90.
- 56 Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HA, et al. A metalloproteinase-generated neoepitope is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995; 95: 2178–86.
- 57 Caterson B. Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulfate. J Biol Chem 1983; 258: 8845–54.
- 58
Poole AR,
Webber A,
Reiner A,
Roughley PJ.
Studies of a monoclonal antibody to skeletal keratan sulfate: importance of antibody valency.
Biochem J
1989;
260:
846–56.
10.1042/bj2600849 Google Scholar
- 59 Sharif M, Osborne DJ, Meadows K, Woodhouse SM, Colvin EM, Shepstone L, et al. The relevance of chondroitine and keratan sulfate markers in normal and arthritic synovial fluid. Br J Rheumatol 1996; 35: 951–7.
- 60 Thonar EJ-MA, Lenz ME, Kintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985; 28: 1367–76.
- 61 Sweet MBE, Coelho A, Schnitzler CM, Schnitzer TJ, Lenz ME, Jaim I, et al. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum 1988; 31: 648–52.
- 62 Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998; 41: 1203–9.
- 63 Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest 1994; 94: 25–33.
- 64 Visco DM, Johnstone B, Hill MA, Jolly GA, Caterson B. Immunohistochemical analysis of 3-B-3(–) and 7-D-4 epitope expression in canine osteoarthritis. Arthritis Rheum 1993; 36: 1718–25.
- 65 Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992; 30: 2268–77.
- 66 Glant TT, Mikecz K, Roughley PJ, Buzaz E, Poole AR. Age-related changes in protein-related epitopes of human articular cartilage proteoglycans. Biochem J 1986; 236: 71–5.
- 67 Antoniou J, Steffen T, Nelson F, Winterbottom N, Hollander AP, Poole RA, et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest 1996; 98: 996–1003.
- 68 Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999; 42: 534–44.
- 69 Mourão PAS. Distribution of chondroitin 4-sulfate and chondroitin 6-sulfate in human articular and growth cartilage. Arthritis Rheum 1988; 31: 1028–33.
- 70 Laurent TC, Larent UBG, Fraser RE. Serum hyaluronan as a disease marker. Ann Med 1996; 28: 241–53.
- 71 Fex F, Eberhardt K, Saxne T. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. BMJ 1997; 36: 1161–5.
- 72 Sharif M, George E, Shepstone L, Knudson W, Thonar EJ-MA, Cushnaghan J, et al. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995; 38: 760–7.
- 73 Manicourt D-H, Poilvache P, Nzeusseu A, van Egeren A, Devogelaer J-P, Lenz ME, et al. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictability in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum 1999; 42: 1861–9.
- 74 Oldberg A, Antonsson P, Lindblom K, Heinegard D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992; 267: 22346–50.
- 75 Newton G, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkis NA, et al. Characterization of human and mouse cartilage oligomeric matrix protein. Genomics 1994; 24: 435–9.
- 76 Rosenberg K, Olson H, Morgelin M, Heinegard D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 1998; 273: 20397–403.
- 77 Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 1995; 10: 330–6.
- 78 Muller G, Michel A, Altenburg E. COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. Connect Tissue Res 1998; 39: 233–44.
- 79 Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998; 41: 997–1006.
- 80 Di Cesare PE, Carlson CSN, Stolerman ES, Hauser N, Tulli H, Paulsson M. Increased degradation and altered tissue distribution of cartilage oligomeric matrix protein in human rheumatoid and osteoarthritic cartilage. J Orthop Res 1996; 14: 946–55.
- 81 Ganu V, Goldberg R, Peppard J, Rediske J, Melton R, Hu S-I, et al. Inhibition of interleukin-1α–induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid. Arthritis Rheum 1998; 41: 2143–51.
- 82 Wollheim FA, Eberhardt KB, Johnson U, Saxne T. HLA DRB1 typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis. Br J Rheumatol 1997; 36: 847–9.
- 83 Lohmander LS, Saxne T, Heunegard DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994; 53: 8–13.
- 84 Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995; 34: 306–10.
- 85 Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999; 42: 2356–64.
- 86 Henrissat B, Bairoch A. New families in the classification of glycosyl hydrolases based on amino-acid sequences similarities. Biochem J 1993; 293: 781–8.
- 87 Rejman JJ, Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the non lactating period. Biochem Biophys Res Commun 1988; 150: 329–34.
- 88 Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 293: 781–8.
- 89 Johansen JS, Jensen HS, Price PA. A new biochemical for joint injury: analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993; 32: 949–55.
- 90 Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL 40: a new potential marker of prognosis location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995; 31A: 1437–42.
- 91 Johansen JS, Hvolris J, Hansen M, Backer V, Lorenszen I, Price PA. Serum YKL-40 levels in healthy children and adults: comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 553–9.
- 92 Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, et al. Chondrex: a new marker of joint disease. Clin Chem 1998; 44: 509–16.
- 93 Garnero P, Jouvenne P, Delmas PD, Miossec P. Serum YKL-40 and joint destruction in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 1999; 63.
- 94 Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen P, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999; 38: 618–26.
- 95 Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 1494–9.
- 96 Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284: 1664–6.
- 97 Shlopov BV, Lie W-R, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 1997; 40: 2065–74.
- 98 Iwase T, Hasegawa Y, Ishiguro N, Ito T, Iwasada S, Kitamura S, et al. Synovial fluid cartilage metabolism marker concentrations in osteonecrosis of the femoral head compared with osteoarthrosis of the hip. J Rheumatol 1997; 25: 527–31.
- 99 Green MJ, Smith J, Gough A, Devlin J, Astin P, Emery P. Serum MMP-3 and MMP-1 correlate with disease activity and predict progression of joint damage in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S173.
- 100 Keyszer G, Lambirini I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease: correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26: 251–8.
